Key Highlights

  • Arecor earned a $0.5 million payment from Ligand Pharmaceuticals, the first commercial milestone under a September 2025 Royalty deal worth up to $11.0 million.
  • Cash and short-term investments stood at £6.1 million at 31 December 2025, up from £3.2 million a year earlier.
  • A co-development agreement with Sequel Med Tech funds Phase 2 trial-enabling work on AT278, Arecor's ultra-concentrated insulin.
  • Peer-reviewed data published in July 2026 supported AT278's pharmacokinetic profile in people with type 2 diabetes.
  • Cash runway is guided into May 2027 under the company's base case.

AIM-listed Arecor Therapeutics has collected the first commercial milestone under its royalty deal with Ligand Pharmaceuticals, a modest but symbolic step as the group leans on non-dilutive cash to fund its ultra-concentrated insulin programme through 2027.

Arecor Therapeutics (LSE:AREC), the Cambridge-based formulation specialist behind the Arestat drug-delivery platform, has reached a small but telling milestone. On 26 March 2026 the AIM-listed company told shareholders it had earned a $0.5 million payment from Ligand Pharmaceuticals, the first commercial trigger under a royalty-monetisation agreement struck last autumn. For a clinical-stage biotech that has spent years burning cash on insulin reformulation, it is proof that older Assets can still generate real income today.

What Happened

The payment stems from a two-part deal signed in September 2025. Under the monetisation agreement, Arecor sold Ligand Pharmaceuticals royalty rights to AT220, an Arestat-enhanced biosimilar, and milestone and technology-access fees tied to AT292, an asset now known as SAR447537 following its earlier licensing route through Inhibrx into Sanofi's pipeline. The arrangement was worth up to $11.0 million (around £8.2 million): $7.0 million upfront at signing, plus up to $4.0 million contingent on commercial milestones. Ligand also received warrants over 1,002,739 Arecor shares, exercisable over ten years at 67.39p.

The March 2026 RNS confirmed the first of those milestones had been hit, releasing $0.5 million to Arecor. Management said a further $0.5 million was expected in the second half of 2026, with the remaining $3 million tied to future commercial progress. The same September 2025 announcement also covered a co-development agreement with Sequel Med Tech, under which each party committed up to $1.3 million to fund Phase 2 trial-enabling work on AT278, Arecor's ultra-concentrated insulin, ahead of a planned combination with Sequel's twiist automated insulin delivery system.

Why It Matters

Small-cap biotechs live and die by cash runway, and non-dilutive income is prized because it does not require issuing new shares. The Ligand payment is not large in absolute terms, but it validates a strategic pivot: rather than commercialising every asset itself, Arecor has begun licensing out mature, de-risked programmes such as AT220 and AT292 to fund development of higher-value candidates, chiefly AT278. It also gives the market confirmation that partner-driven royalty streams, often treated sceptically until cash lands, are starting to convert into real receipts.

Latest Financial and Operational Performance

Arecor's (LSE:AREC) full-year results for 2025, published on 13 April 2026, showed the impact of this shift. Revenue from continuing operations was £1.7 million, against £1.6 million in 2024, while R&D spend fell to £2.7 million from £3.0 million as the group narrowed its focus following the wind-down of its legacy Tetris Pharma product Business . Cash used in Operating Activities dropped to £3.1 million from £5.7 million, and adjusted EBITDA came in at negative £3.5 million, an improvement on the prior year's negative £4.7 million.

Cash and short-term investments stood at £6.1 million at 31 December 2025, up from around £3.2 million a year earlier, largely thanks to the Ligand upfront payment. Management guided that this cash, plus anticipated milestones, should fund operations into May 2027 under its base case, or April 2027 in a worse-case scenario. That compares with the half-year stage, when cash had fallen to just £1.9 million at 30 June 2025, before the Ligand and Sequel deals were signed.

Key Numbers

  • $0.5m first commercial milestone paid by Ligand Pharmaceuticals, announced 26 March 2026
  • Up to $11.0m (c.£8.2m) total value of the September 2025 Ligand monetisation deal, including $7.0m received upfront
  • $1.3m each committed by Arecor and Sequel Med Tech for AT278 Phase 2 trial-enabling work
  • £6.1m cash and short-term investments at 31 December 2025 (2024: c.£3.2m)
  • £2.7m Research and Development spend in FY2025 (2024: £3.0m)
  • Cash runway guided into May 2027 under the base case
  • Shares recently trading around 135p, valuing the company at roughly £42 million, against a 52-week range of 125p to 280p

Growth Opportunities

The central prize remains AT278, Arecor's 500 U/mL ultra-concentrated, ultra-rapid-acting insulin aspart, which the company describes as the only asset of its kind in development. Data published in Diabetes, Obesity and Metabolism on 30 July 2026 reported favourable pharmacokinetic and pharmacodynamic properties in people with type 2 diabetes regardless of body mass index , adding peer-reviewed weight to earlier Phase 1 findings. Positive FDA feedback on the Phase 2 study design has cleared the path for a trial pairing AT278 with Sequel's twiist delivery system, targeted for the second half of 2026, with both partners intending to negotiate a broader commercialisation agreement covering that stage and beyond. Beyond insulin, Arecor's earlier-stage oral peptide platform has generated positive in-vitro results and a filed Patent application, with non-clinical studies planned through 2026; the company was also named by Clarivate in early August 2026 among seven firms to watch in next-generation obesity therapeutics.

Risks Investors Should Know

Arecor remains a loss-making clinical-stage company reliant on partners and milestone triggers it does not fully control. The remaining $3 million of Ligand-linked payments, including the $0.5 million Tranche expected in the second half of 2026, are contingent on commercial events at partners' businesses, not guaranteed dates. AT278 has yet to enter Phase 2 trials, and the "broader co-development and commercialisation Partnership " with Sequel is, for now, a stated intention rather than a signed agreement. Cash runway guidance to April or May 2027 assumes milestones land roughly as expected; slippage would tighten the position and could necessitate further fundraising, dilutive or otherwise. As with any clinical-stage biopharmaceutical, regulatory, trial-execution and competitive risks in the crowded insulin and obesity markets persist throughout.

What to Watch Next

Investors should watch for the second Ligand milestone, confirmation of AT278's Phase 2 trial start, and progress on formalising the broader Sequel partnership. Updates on the oral peptide platform, plus any further licensing deals involving AT247 or other Arestat-based assets, will also show whether the non-dilutive funding model can be repeated.

Outlook

The $0.5 million Ligand payment is a modest sum against an £8.2 million deal and a company valued at roughly £42 million, but its significance lies in what it shows: Arecor's strategy of monetising mature royalty streams to fund its higher-potential pipeline is beginning to function as designed. With runway extended into 2027 and AT278's Phase 2 trial approaching, the coming year should show whether this platform can turn scientific promise into recurring, partner-funded income.